Radium 223 without androgen deprivation therapy (ADT) in patients (Pts) with biochemically recurrent prostate cancer (BCR) and PET findings in the bones.
Melissa L. Abel(National Institutes of Health), Ravi A. Madan(National Cancer Institute), Katherine Lee-Wisdom(National Institutes of Health), Amy Hankin(National Institutes of Health), Choyke Pl(National Institutes of Health), Fatima Karzai(National Institutes of Health), Esther Mena(National Institutes of Health), Philip M. Arlen(Dana-Farber Cancer Institute), Megan Hausler(National Institutes of Health), Liza Lindenberg(National Cancer Institute), Jeanny B. Aragon-Ching(Virginia Cancer Institute), Yolanda McKinney(National Cancer Institute), A. B. Warner(National Institutes of Health), Clara Chen(National Institutes of Health), James L. Gulley(Center for Cancer Research), William D. Figg(National Institutes of Health), Frank Lin(National Institutes of Health), Lisa M. Cordes(National Institutes of Health Clinical Center)
Cited by 0
Related Papers
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|975
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
|Clinical Cancer Research|2018|415
Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer
|Clinical Cancer Research|2005|371
Phase I Study in Advanced Cancer Patients of a Diversified Prime-and-Boost Vaccination Protocol Using Recombinant Vaccinia Virus and Recombinant Nonreplicating Avipox Virus to Elicit Anti–Carcinoembryonic Antigen Immune Responses
|Journal of Clinical Oncology|2000|357
Cancer Survivorship—Genetic Susceptibility and Second Primary Cancers: Research Strategies and Recommendations
|JNCI Journal of the National Cancer Institute|2006|345